Replies to post #80183 on Biotech Values

[DewDiligence]

MNTA: Any prediction on the [M118] partner? My guess would be NVS. As far as I am aware, NVS has no NME in the works for an anticoagulant, and the Sandoz relationship for the Lovenox generic seems to be in good shape.

Any Big Pharma would be a logical partner for M118 insofar as: i) the commercial upside is large; ii) all Big Pharma have a cardiovascular salesforce; and iii) nobody has a competing drug.

I don’t think MNTA’s relationship with Sandoz (the generic-drug division of NVS) necessarily makes it more likely that the branded-drug division of NVS will want to partner with MNTA on M118. MNTA’s choice of a partner will boil down to which company makes the best offer, IMO.